Allopurinol may increase CV risk, mortality in gout compared to benzbromarone: Study
South Korea: Results from a large population-based cohort showed that allopurinol is related to an increased risk of all-cause mortality and composite cardiovascular (CV) events versus benzbromarone. Benzbromarone may reduce mortality and cardiovascular (CV) risk in gout patients. The study appears in the European Heart Journal.
Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a pro-inflammatory milieu. Risks among men with gout are reported to be higher at 1.28% for total mortality and fatal cardiovascular events.
Eun Ha Kang, Seoul National University Bundang Hospital, Seongnam, South Korea, and colleagues aimed to compare CV risk among patients with gout who initiated allopurinol vs. benzbromarone treatment.
The study was a cohort study conducted in Korean National Health Insurance claims data (2002-17) of 124 434 gout patients who initiated either allopurinol (n = 103 695) or benzbromarone (n = 20 739), matched on propensity score at a 5:1 ratio. The primary outcome was a composite CV endpoint of myocardial infarction, stroke/transient ischaemic attack, or coronary revascularization.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.